Zydus Lifesciences532321Pharmaceuticals
Zydus Lifesciences got positive phase 3 trial response for a liver disease drug, under US FDA review
By ScoutQuest · · 1 min read
Heard on business television between 08:26:09 - 08:29:09 IST.
- Company conducted phase three trial for a liver disease drug
- Positive response received, currently under review with US FDA
- Company plans to launch in the US market around March 2027, subject to FDA approval
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Zydus Lifesciences
Zydus Lifesciences Q2 FY27 results on Nov 4, 2026; post-results earnings call same day at 3:30 p.m. IST
24 Oct 2026
Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production
21 Oct 2026
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity
21 Oct 2026
Source: Live TV News Channel · 13 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.